UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting

Supportive care in cancer, 2024-01, Vol.32 (1), p.26-26, Article 26

2024

Volltextzugriff (PDF)

Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study

European journal of cancer (1990), 2024-07, Vol.205, p.114099, Article 114099

2024

Volltextzugriff (PDF)

Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy

Acta oncologica, 2023-01, Vol.62 (1), p.62-69

2023

Volltextzugriff (PDF)

Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation

Supportive care in cancer, 2024-01, Vol.32 (1), p.53-53, Article 53

2024

Volltextzugriff (PDF)

Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences

Supportive care in cancer, 2022-02, Vol.30 (2), p.1181-1190

2022

Volltextzugriff (PDF)

2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential

Supportive care in cancer, 2024-01, Vol.32 (1), p.37-37, Article 37

2024

Volltextzugriff (PDF)

Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma

European journal of cancer (1990), 2024-05, Vol.202, p.114023-114023, Article 114023

2024

Volltextzugriff (PDF)

Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial

The lancet oncology, 2016-04, Vol.17 (4), p.509-518

2016

Volltextzugriff (PDF)

Response to Vitetta et al

Supportive care in cancer, 2022-11, Vol.30 (11), p.8623-8624

2022

Volltextzugriff (PDF)

2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting

Supportive care in cancer, 2017, Vol.25 (1), p.309-316

2017

Volltextzugriff (PDF)

Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults

Expert review of clinical pharmacology, 2019-07, Vol.12 (7), p.661-680

2019

Volltextzugriff (PDF)

Organ-specific accuracy of [18F]FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor

Japanese journal of radiology, 2024-07, Vol.42 (7), p.753-764

2024

Volltextzugriff (PDF)

A national repository of complete radiotherapy plans: design, Results, and experiences

Acta oncologica, 2023-10, Vol.62 (10), p.1161-1168

2023

Volltextzugriff (PDF)

Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study

Supportive care in cancer, 2024-05, Vol.32 (5), p.281-281, Article 281

2024

Volltextzugriff (PDF)

New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting

Expert opinion on pharmacotherapy, 2016-08, Vol.17 (12), p.1623-1629

2016

Volltextzugriff (PDF)

Multinational study exploring patients’ perceptions of side-effects induced by chemo-radiotherapy

Radiotherapy and oncology, 2015-11, Vol.117 (2), p.333-337

2015

Volltextzugriff (PDF)

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study

Cancers, 2021-11, Vol.13 (21), p.5550

2021

Volltextzugriff (PDF)

Value of 2-[18F]FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review

Clinical and translational imaging : reviews in nuclear medicine and molecular imaging, 2024-04, Vol.12 (2), p.187-195

2024

Volltextzugriff (PDF)

Correction: Value of 2-[18 F]FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review

Clinical and translational imaging : reviews in nuclear medicine and molecular imaging, 2024, Vol.12 (3), p.373-373

2024

Volltextzugriff (PDF)

Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin—a phase II study

Supportive care in cancer, 2013-12, Vol.21 (12), p.3425-3431

2013

Volltextzugriff (PDF)

2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential

Supportive care in cancer, 2017, Vol.25 (1), p.297-301

2017

Volltextzugriff (PDF)

Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting

Expert review of anticancer therapy, 2012-02, Vol.12 (2), p.139-150

2012

Volltextzugriff (PDF)

Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting

Expert opinion on drug safety, 2011-05, Vol.10 (3), p.449-462

2011

Volltextzugriff (PDF)

Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases—A Danish Real-World Cohort

Cancers, 2024-07, Vol.16 (14), p.2559

2024

Volltextzugriff (PDF)

Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes

Journal of clinical medicine, 2022-03, Vol.11 (7), p.1862

2022

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(37)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Oncology
(22)
Humans
(20)
Antineoplastic Agents - Adverse Effects
(12)
Medicine
(12)
Medicine & Public Health
(12)
Nausea
(12)
Cancer
(11)
Chemotherapy
(11)
Vomiting
(11)
Antiemetics - Therapeutic Use
(10)
Nausea - Prevention & Control
(10)
Vomiting - Prevention & Control
(10)
Health Care Sciences & Services
(9)
Nausea - Chemically Induced
(9)
Nursing
(9)
Nursing Research
(9)
Pain Medicine
(9)
Rehabilitation
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting

Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study

Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy

Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation

Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences

2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential

Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma

Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial

Response to Vitetta et al

2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting

Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults

Organ-specific accuracy of [18F]FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor

A national repository of complete radiotherapy plans: design, Results, and experiences

Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study

New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting

Multinational study exploring patients’ perceptions of side-effects induced by chemo-radiotherapy

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study

Value of 2-[18F]FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review

Correction: Value of 2-[18 F]FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review

Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin—a phase II study

2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential

Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting

Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting

Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases—A Danish Real-World Cohort

Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes

Suchergebnisse filtern